| Nov 21 |
Amneal gets FDA approval for generic Byetta, resubmits DHE NDA
|
| Nov 21 |
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
|
| Nov 9 |
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
| Nov 8 |
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript
|
| Nov 8 |
Amneal Pharmaceuticals Non-GAAP EPS of $0.16 beats by $0.02, revenue of $702.5M beats by $8.77M
|
| Nov 8 |
Amneal Reports Third Quarter 2024 Financial Results
|
| Nov 7 |
Amneal Pharmaceuticals Q3 2024 Earnings Preview
|
| Oct 31 |
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211%
|
| Oct 21 |
Amneal gets FDA nod for NDA of its neuromuscular disorder treatment
|
| Oct 21 |
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
|
